JP2008074748A - Skin care preparation - Google Patents
Skin care preparation Download PDFInfo
- Publication number
- JP2008074748A JP2008074748A JP2006254537A JP2006254537A JP2008074748A JP 2008074748 A JP2008074748 A JP 2008074748A JP 2006254537 A JP2006254537 A JP 2006254537A JP 2006254537 A JP2006254537 A JP 2006254537A JP 2008074748 A JP2008074748 A JP 2008074748A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- extract
- sample
- action
- kouyamaki
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 74
- 241000196324 Embryophyta Species 0.000 claims abstract description 24
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 239000002537 cosmetic Substances 0.000 claims abstract description 21
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 19
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 19
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 239000002798 polar solvent Substances 0.000 claims abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 13
- 239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 10
- 229940121363 anti-inflammatory agent Drugs 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 239000003125 aqueous solvent Substances 0.000 claims abstract description 6
- 241001138409 Sciadopitys verticillata Species 0.000 claims abstract description 5
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 37
- 230000002087 whitening effect Effects 0.000 claims description 13
- 210000003491 skin Anatomy 0.000 abstract description 43
- 210000004927 skin cell Anatomy 0.000 abstract description 6
- 230000036541 health Effects 0.000 abstract description 5
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 206010040829 Skin discolouration Diseases 0.000 abstract 2
- 239000007854 depigmenting agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 description 56
- 230000000694 effects Effects 0.000 description 55
- 239000000523 sample Substances 0.000 description 52
- 238000002835 absorbance Methods 0.000 description 34
- 238000000605 extraction Methods 0.000 description 29
- -1 lipid peroxide Chemical class 0.000 description 26
- 102000016387 Pancreatic elastase Human genes 0.000 description 23
- 108010067372 Pancreatic elastase Proteins 0.000 description 23
- 230000008099 melanin synthesis Effects 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 102000003425 Tyrosinase Human genes 0.000 description 21
- 108060008724 Tyrosinase Proteins 0.000 description 21
- 239000000126 substance Substances 0.000 description 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 18
- 239000001301 oxygen Substances 0.000 description 18
- 229910052760 oxygen Inorganic materials 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- 239000012488 sample solution Substances 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000009471 action Effects 0.000 description 16
- 235000006708 antioxidants Nutrition 0.000 description 16
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 14
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 102000004190 Enzymes Human genes 0.000 description 13
- 108090000790 Enzymes Proteins 0.000 description 13
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 12
- 230000002292 Radical scavenging effect Effects 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- 150000002632 lipids Chemical class 0.000 description 12
- 238000007254 oxidation reaction Methods 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000003647 oxidation Effects 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 230000002000 scavenging effect Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 239000006210 lotion Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229960001340 histamine Drugs 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 102000016942 Elastin Human genes 0.000 description 5
- 108010014258 Elastin Proteins 0.000 description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 229920002549 elastin Polymers 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000020778 linoleic acid Nutrition 0.000 description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 5
- 230000009759 skin aging Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 206010040954 Skin wrinkling Diseases 0.000 description 4
- 102000019197 Superoxide Dismutase Human genes 0.000 description 4
- 108010012715 Superoxide dismutase Proteins 0.000 description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 239000004205 dimethyl polysiloxane Substances 0.000 description 4
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 4
- 230000008034 disappearance Effects 0.000 description 4
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 239000002304 perfume Substances 0.000 description 4
- 229960005323 phenoxyethanol Drugs 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 4
- 230000037303 wrinkles Effects 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- QZKRHPLGUJDVAR-UHFFFAOYSA-K EDTA trisodium salt Chemical compound [Na+].[Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O QZKRHPLGUJDVAR-UHFFFAOYSA-K 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- ASKIVFGGGGIGKH-UHFFFAOYSA-N 2,3-dihydroxypropyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OCC(O)CO ASKIVFGGGGIGKH-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 241000912433 Paulinia Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 239000012752 auxiliary agent Substances 0.000 description 2
- 239000007844 bleaching agent Substances 0.000 description 2
- 238000006388 chemical passivation reaction Methods 0.000 description 2
- 238000005238 degreasing Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
- 229960000735 docosanol Drugs 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 2
- 230000007760 free radical scavenging Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000004694 pigment cell Anatomy 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- HOVAGTYPODGVJG-UVSYOFPXSA-N (3s,5r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol Chemical compound COC1OC(CO)[C@@H](O)C(O)[C@H]1O HOVAGTYPODGVJG-UVSYOFPXSA-N 0.000 description 1
- NJYFRQQXXXRJHK-UHFFFAOYSA-N (4-aminophenyl) thiocyanate Chemical compound NC1=CC=C(SC#N)C=C1 NJYFRQQXXXRJHK-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241001237961 Amanita rubescens Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 235000021357 Behenic acid Nutrition 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- 241000644798 Canarium <sea snail> Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- IUMSDRXLFWAGNT-UHFFFAOYSA-N Dodecamethylcyclohexasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 IUMSDRXLFWAGNT-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 244000075898 Lantana strigocamara Species 0.000 description 1
- 241000218922 Magnoliophyta Species 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000187664 Nerium oleander Species 0.000 description 1
- 241000207834 Oleaceae Species 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000511979 Plumeria Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002197 Sodium polyaspartate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229940069521 aloe extract Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- IRERQBUNZFJFGC-UHFFFAOYSA-L azure blue Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[S-]S[S-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] IRERQBUNZFJFGC-UHFFFAOYSA-L 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 239000003788 bath preparation Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 229940116226 behenic acid Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000004566 building material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000011538 cleaning material Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007323 disproportionation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- KWLMIXQRALPRBC-UHFFFAOYSA-L hectorite Chemical compound [Li+].[OH-].[OH-].[Na+].[Mg+2].O1[Si]2([O-])O[Si]1([O-])O[Si]([O-])(O1)O[Si]1([O-])O2 KWLMIXQRALPRBC-UHFFFAOYSA-L 0.000 description 1
- 229910000271 hectorite Inorganic materials 0.000 description 1
- 230000010196 hermaphroditism Effects 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical compound FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007934 lip balm Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000005474 octanoate group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000008257 shaving cream Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- QPQANCNBWQXGTQ-UHFFFAOYSA-N trihydroxy(trimethylsilylperoxy)silane Chemical compound C[Si](C)(C)OO[Si](O)(O)O QPQANCNBWQXGTQ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 235000013799 ultramarine blue Nutrition 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000002349 well water Substances 0.000 description 1
- 235000020681 well water Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
この発明は、身体外表面部である皮膚に、塗布、貼付、噴霧などの処方により塗って用いる皮膚外用剤、詳しくは紫外線暴露や加齢による皮膚の老化防止などに有効な皮膚外用剤に関するものである。 The present invention relates to a skin external preparation used by applying to the skin which is the outer surface of the body according to a prescription such as application, sticking or spraying, and more particularly to a skin external preparation effective for preventing skin aging due to UV exposure or aging. It is.
一般に、皮膚は酸素や紫外線に曝されており、皮膚の老化に伴って起こる変化、すなわち、シワ、クスミ、キメの消失、弾力性の低下などは、紫外線が大きく関与していることが知られている。 In general, the skin is exposed to oxygen and ultraviolet rays, and it is known that ultraviolet rays are greatly involved in changes that occur with aging of the skin, that is, wrinkles, rashes, disappearance of texture, reduced elasticity, etc. ing.
また、紫外線により発生する皮膚細胞に発生する活性酸素のうち、フリーラジカル型のものは脂質等の酸化を受け易い基質と反応すると、連鎖的な酸化反応を誘発し、組織に対してダメージを与える。 In addition, free radicals of active oxygen generated in skin cells generated by ultraviolet rays react with a substrate that is susceptible to oxidation, such as lipid, to induce a chain oxidation reaction and damage tissues. .
近年では、紫外線により発生した種々の活性酸素が、皮脂や脂質の過酸化、蛋白変性、酵素阻害等を引き起こし、それが短期間に皮膚の炎症等を誘発し、長期間に亘れば老化やガンなどの原因となると考えられている。 In recent years, various active oxygens generated by ultraviolet rays cause sebum and lipid peroxidation, protein denaturation, enzyme inhibition, etc., which induce skin inflammation in a short period of time, It is thought to cause cancer.
また、活性酸素や過酸化脂質などの関連物質は、アトピー性皮膚炎や接触皮膚炎、乾癬などの皮膚疾患にも関与するとも考えられている。 Related substances such as active oxygen and lipid peroxide are also considered to be involved in skin diseases such as atopic dermatitis, contact dermatitis, and psoriasis.
皮膚老化や皮膚疾患については、例えばビタミンＣやビタミンＥなどは、生体内におけるフリーラジカル捕捉型抗酸化性物質として知られ、ＢＨＴやＢＨＡなどの合成抗酸化性物質も知られている。 Regarding skin aging and skin diseases, for example, vitamin C and vitamin E are known as free radical scavenging antioxidant substances in vivo, and synthetic antioxidant substances such as BHT and BHA are also known.
フリーラジカルを消去する能力、すなわち活性酸素の消去能を有する公知の生薬としては、例えばオスベッキア属（ヒメノボタン属とも呼ばれる。）に属する多年生草本植物の抽出物、キョウチクトウ科のプルメリア属に属する植物の抽出物、カンラン科の常緑高木であるカナリウム属に属する植物の抽出物、クマツヅラ科に属する小低木のランタナの抽出物等が知られている。 Known herbal medicines having the ability to scavenge free radicals, that is, the ability to scavenge active oxygen include, for example, extracts of perennial herbaceous plants belonging to the genus Osbecchia (also referred to as Hymenobactus), and those belonging to the genus Plumeria belonging to the oleander family. An extract, an extract of a plant belonging to the genus Canarium, which is an evergreen tree of an orchidaceae, and an extract of a lantana of a small shrub belonging to the family Oleaceae are known.
また、皮膚のシミ、ソバカスなどの色素沈着は、紫外線の刺激などにより、表皮色素細胞内でメラニン生成が亢進し、メラニンが表皮に過剰に沈着することに因る。 In addition, pigmentation of skin spots, buckwheat and the like is caused by melanin being excessively deposited in the epidermis due to increased production of melanin in epidermal pigment cells due to stimulation of ultraviolet rays.
メラニンは表皮色素細胞内で生合成された酵素チロシナーゼの働きにより、チロシンからドーパ、ドーパからドーパキノンに変化し、ついで５，６−ジヒドロキシインドフェノール等の中間体を経て形成されるものと考えられ、このようなメラニン生成過程を抑制し、または生成したメラニンを淡色化することにより、皮膚の黒化（皮膚色素沈着症）やシミを予防し、治療し又は改善する。 Melanin is thought to be formed via an intermediate such as 5,6-dihydroxyindophenol, by the action of the enzyme tyrosinase biosynthesized in epidermal pigment cells, changing from tyrosine to dopa, from dopa to dopaquinone, By suppressing such a melanin production process or by lightening the produced melanin, skin darkening (skin pigmentation) and spots are prevented, treated or improved.
従来、メラニンの生成を抑制するために、Ｌ−アスコルビン酸を大量に投与する方法、グルタチオン等を皮下注射する方法、コウジ酸、システイン、ハイドロキノン等を軟膏、クリーム、ローション等の形態にして局所に塗布する方法が挙げられる。チロシナーゼの活性を抑制する生薬としては、例えば籐茶抽出物、ヤナギタケ抽出物等が知られている。 Conventionally, in order to suppress the production of melanin, a method of administering a large amount of L-ascorbic acid, a method of subcutaneous injection of glutathione, etc., kojic acid, cysteine, hydroquinone etc. in the form of ointment, cream, lotion, etc. locally The method of apply | coating is mentioned. Known herbal medicines that suppress the activity of tyrosinase include, for example, rattan tea extract and willow bamboo extract.
また、色素沈着の予防および改善のために、マキ科植物ダクリジウム ビフォルメ(Dacridium biforme)の水溶性有機溶媒などの抽出物を配合した化粧品が知られている（特許文献１）。 In addition, for prevention and improvement of pigmentation, a cosmetic is known in which an extract such as a water-soluble organic solvent of the crustacean plant Dacridium biforme is blended (Patent Document 1).
ところで、皮膚は、外層から表皮、真皮、皮下組織と大きく三つに分類され、外界からの衝撃を吸収する真皮は、主に、コラーゲン、エラスチン、線維芽細胞から主としてなり、老化と共にコラーゲンおよびエラスチンの劣化、減少あるいは変性により、シワ、キメの消失、弾力性の低下等の老化症状が現れる。 By the way, the skin is roughly classified into the outer layer, epidermis, dermis, and subcutaneous tissue, and the dermis that absorbs shock from the outside mainly consists of collagen, elastin, and fibroblasts. Aging symptoms such as wrinkles, disappearance of texture, reduced elasticity, etc. appear due to deterioration, reduction or degeneration of the skin.
健状な真皮の中では、コラーゲンおよびエラスチンは古くなったものは吸収され、または排出され、新たにコラーゲンおよびエラスチンが線維芽細胞から生成されることにより、これらの一定の質および量が恒常的に保たれる。 In the healthy dermis, collagen and elastin are absorbed or excreted as they become old, and new constant collagen and elastin is produced from fibroblasts, making these constant quality and quantity constant. To be kept.
しかし、年齢を重ねると、外的および内的な要因において、その恒常性は崩れ、さらには線維芽細胞由来のエラスターゼが必要以上にエラスチンを分解することにより、老化症状が促進する。 However, with age, the homeostasis is lost in external and internal factors, and fibroblast-derived elastase degrades elastin more than necessary, thereby promoting aging symptoms.
このような老化症状の改善のために、エラスターゼ活性抑制作用を有する生薬として、例えば黒米抽出物やアロエ抽出物が知られている。 In order to improve such aging symptoms, for example, black rice extract and aloe extract are known as herbal medicines having an elastase activity inhibitory action.
また、花粉症、アレルギー性鼻炎、アトピー性皮膚炎などのアレルギー性疾患は、体内におけるヒスタミンの遊離の他、活性酸素やラジカルなどのアレルギー誘発物質の発生などが原因となって生じる。 In addition, allergic diseases such as hay fever, allergic rhinitis and atopic dermatitis are caused by the release of histamine in the body and the generation of allergens such as active oxygen and radicals.
ヒスタミン等のアレルギー誘発物質と同時に放出されるβ−ヘキソサミニダーゼ活性抑制作用を有する生薬として、ムクロジ科のつる性木本であるパウリニア・ピンナタの抽出物等が報告されている（特許文献２参照）。 As a crude drug having an inhibitory action on β-hexosaminidase activity released simultaneously with allergens such as histamine, an extract of Paulinia pinnata, which is a vine woody plant of Mucuridae, has been reported (Patent Document 2). reference).
しかし、前記した合成抗酸化性物質を配合した化粧品などの薬剤では、合成物質処方の過剰は望ましいことではなく、できるだけ天然抽出物に由来する多成分系の有効性を発揮させることが要望されている。 However, in the case of drugs such as cosmetics containing the above-mentioned synthetic antioxidant substances, excessive formulation of synthetic substances is not desirable, and there is a demand for exhibiting the effectiveness of multi-component systems derived from natural extracts as much as possible. Yes.
また、天然系から抽出される有効成分は、植物の種類が異なれば含有される成分が異なることが予想され、そのような有効成分は種類別に充分に知られていないのが実情であるといえる。 In addition, active ingredients extracted from natural systems are expected to contain different ingredients if the type of plant is different, and it can be said that such active ingredients are not well known by type. .
例えば、前記したマキ科植物ダクリジウム ビフォルメ(Dacridium biforme)は、主にニュージーランドやオーストラリアに産し、一方、後述する本邦特産種であるのコウヤマキ科（一科一属一種）とは系統分類的上の「科」レベルで植物学的特徴が全く異なる植物である。 For example, the above-mentioned Dacridium biforme is mainly produced in New Zealand and Australia, while it is phylogenetic from the Japanese special species that will be described later. Plants with completely different botanical characteristics at the “family” level.
また、ムクロジ科のつる性木本であるパウリニア・ピンナタは、裸子植物であり、コウヤマキの被子植物とは、系統分類的上の「門」レベルで植物学的特徴が全く異なる植物である。 Also, Paulinia pinnata, a vine woody plant belonging to the genus Muclocidae, is a gymnosperm, and is a plant that is completely different from the angiosperms of Kouyamaki at the phylogenetic "gate" level.
さらに、前記したダクリジウム ビフォルメに関する有用性に関する知見は、特許文献１にも記載されているように、メラニン生成抑制作用のみであり、その他に有用な作用を及ぼす知見はなかった。 Furthermore, as described in Patent Document 1, only the melanin production-inhibiting action is known, and there is no other knowledge that has any useful action.
このように天然の皮膚外用剤抽出材料は、研究開発による充分な知見が得られておらず、抽出成分として安全性及び生成性に優れていて日常的に摂取可能であり、かつ高い活性酸素消去作用を有すると共に、ラジカル消去作用、脂質酸化抑制作用、チロシナーゼ活性抑制作用、メラニン生成抑制作用またはエラスターゼ活性抑制作用、及びβ−ヘキソサミニダーゼ活性抑制作用などを有するものは得られていない。 As described above, natural skin external preparation extraction materials have not obtained sufficient knowledge through research and development, are excellent in safety and productivity as extraction components, can be ingested on a daily basis, and eliminate high active oxygen. In addition to the action, no radical scavenging action, lipid oxidation inhibitory action, tyrosinase activity inhibitory action, melanin production inhibitory action or elastase activity inhibitory action, and β-hexosaminidase activity inhibitory action have been obtained.
そこで、この発明の課題は、上記した問題点を解決して、皮膚外用剤の有効成分として有用性の高い植物を特定し、確実に利用できるようにすることであり、特に抗酸化性、美白性、抗老化性または抗炎症性を有していて皮膚細胞への健康増進性に優れた植物由来の抽出成分を発見し、それを用いて皮膚細胞への健康増進性に優れた新規な皮膚外用剤とすることである。 Accordingly, an object of the present invention is to solve the above-described problems and to identify a plant that is highly useful as an active ingredient of an external preparation for skin and ensure that it can be used. Found a plant-derived extract ingredient that has excellent sex, anti-aging or anti-inflammatory properties and excellent health promotion to skin cells, and used it to create new skin with excellent health promotion to skin cells It is to make it an external preparation.
さらに具体的な課題に言及すれば、この発明では、優れた活性酸素消去（捕捉）能を有し、安全性の高い抗酸化能のある化粧料等の皮膚外用剤とし、また、優れたチロシナーゼ活性抑制作用若しくはメラニン生成抑制作用または両作用を併有し、安全性の高い美白剤またはこれを配合した化粧料等の皮膚外用剤とし、さらには優れたエラスターゼ活性抑制作用を有し、安全性の高い抗老化剤またはこれを配合した化粧料等の皮膚外用剤とし、また優れたβ−ヘキソサミニダーゼ活性抑制作用を有する安全性の高い抗炎症剤またはこれを配合した化粧料等の皮膚外用剤とすることが課題である。 If more specific problems are mentioned, in the present invention, an external skin preparation such as cosmetics having excellent active oxygen scavenging (capturing) ability and high safety and antioxidative ability, and excellent tyrosinase It has an activity inhibitory action or melanin production inhibitory action or both actions, making it a highly safe whitening agent or a skin external preparation such as cosmetics containing this, and also has an excellent elastase activity inhibitory action and safety High anti-aging agent or skin external preparation such as cosmetics containing the same, and excellent anti-inflammatory agent having an excellent inhibitory action on β-hexosaminidase activity or skin such as cosmetics containing the same It is a problem to make it an external preparation.
上記の課題を解決するために、この発明では、コウヤマキ（Sciadopitys verticillata）の植物体の極性溶媒抽出物を、抗酸化性、美白性、抗老化性または抗炎症性の有効成分として含有する皮膚外用剤としたのである。 In order to solve the above-mentioned problems, in the present invention, an external application for skin containing a polar solvent extract of a plant body of Sciadopitys verticillata as an active ingredient of antioxidant, whitening, anti-aging or anti-inflammatory properties It was an agent.
上記したように構成されるこの発明の皮膚外用剤は、コウヤマキの植物体の何れかの部分を極性溶媒で抽出したものを配合したことにより、極性溶媒に浸出性のある成分中に含まれる有効成分により、抗酸化性、美白性、抗老化性または抗炎症性の少なくとも１以上の作用を奏する。 The external preparation for skin of the present invention configured as described above is an effective ingredient contained in a component leaching into a polar solvent by blending a part extracted from a plant of Koyamaki with a polar solvent. Depending on the component, it exhibits at least one action of antioxidation, whitening, anti-aging, and anti-inflammatory.
前記の極性溶媒としては、水、水性溶媒または親水性有機溶媒を採用することができる皮膚外用剤である。 As said polar solvent, it is a skin external preparation which can employ | adopt water, an aqueous solvent, or a hydrophilic organic solvent.
また、前記の植物体としては、果実、葉、花、種子、樹皮、樹幹、樹枝および根から選ばれる１部分以上の植物体を採用して、充分に確かなものが得られる。 Moreover, as said plant body, the plant body of 1 part or more chosen from a fruit, a leaf, a flower, a seed, a bark, a trunk, a tree branch, and a root is employ | adopted, and a sufficiently reliable thing is obtained.
極性溶媒抽出物が、抽出条件として、大気圧で室温、超臨界または亜臨界のいずれかの抽出条件を採用して得られた極性溶媒抽出物であれば、皮膚外用剤の前記効用はより確実に奏される。 If the polar solvent extract is a polar solvent extract obtained by adopting the extraction conditions of room temperature, supercritical or subcritical at atmospheric pressure as the extraction conditions, the above-mentioned effect of the external preparation for skin is more reliable. To be played.
また、皮膚外用剤は、有効成分を用途別に適用して、化粧料、抗酸化剤、美白剤、抗老化剤または皮膚外用剤などの製剤形態に適用できる。 In addition, the external preparation for skin can be applied to preparation forms such as cosmetics, antioxidants, whitening agents, anti-aging agents, or external preparations for skin by applying the active ingredient according to the use.
この発明は、コウヤマキ（Sciadopitys verticillata）の植物体の極性溶媒抽出物を含有する皮膚外用剤としたので、優れたフリーラジカル捕捉能を有すると共に安全性は高く、抗酸化作用、チロシナーゼ活性抑制作用、メラニン生成抑制作用、美白作用、エラスターゼ活性抑制作用、抗老化作用またはβ−ヘキソサミニダーゼ活性抑制作用を発揮するから、皮膚細胞への健康増進性に優れた実用性の高い皮膚外用剤となる利点がある。 Since this invention is an external preparation for skin containing a polar solvent extract of a plant body of Koyamaki (Sciadopitys verticillata), it has excellent free radical scavenging ability and high safety, antioxidant action, tyrosinase activity inhibitory action, Melanin production inhibitory action, whitening action, elastase activity inhibitory action, anti-aging action, or β-hexosaminidase activity inhibitory action, so it is a highly practical skin external preparation with excellent health promotion to skin cells. There are advantages.
この発明の抗酸化剤、美白剤、抗老化剤または抗炎症剤などの皮膚外用剤は、特定のコウヤマキ科コウヤマキ属のコウヤマキ（Sciadopitys verticillata）（高野槇またはホンマキとも別称される。）（以下、単にコウヤマキと記す。）の抽出物を有効成分として含有するものである。 The topical skin preparation such as an antioxidant, whitening agent, anti-aging agent or anti-inflammatory agent of the present invention is a specific species of the genus Koyamaki (Sciadopitys verticillata) (also referred to as Takano Kaoru or Honmaki) (hereinafter also referred to as “Konoyaki”). It is simply referred to as Kouyamaki.) As an active ingredient.
ここで、コウヤマキの抽出物には、抽出液、この抽出液の希釈液若しくは濃縮液、抽出液を乾燥して得られる乾燥物、若しくは粗抽出物または精製物並びに超臨界抽出物若しくは亜臨界抽出物のいずれが含まれていてもよい。 Here, the extract of Kouyamaki includes an extract, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a crude extract or a purified product, and a supercritical extract or subcritical extract. Any of the objects may be included.
抽出原料のコウヤマキは、雌雄同株の一科一属一種の植物で、属名には樹形によるskiadeion（傘）とpitys（松）、種小名は針葉の発生状態によるverticillus(輪生体)から由来し、和名の由来は高野山に多いことからである。そして、緻密で端正な円錐になる樹形の美しさからも世界三大美(公園)樹とされている植物である。 Kouyamaki, a raw material for extraction, is a plant belonging to the same genus of the same hermaphrodite. This is because the origin of the Japanese name is high in Mt. Koya. And it is a plant that is considered to be the world's three most beautiful (park) trees from the beauty of the tree shape that becomes a dense and neat cone.
上記コウヤマキは、常緑高木で幹は直立し、樹高は３５〜４０ｍで樹皮は灰褐色から赤褐色で縦に裂け、鱗片状にはがれる。また、長枝の鱗片葉は、らせん状に互生し、短枝の葉は２本の葉が合着した線形２０〜４０本の葉が輪生または束生する。線形の葉は、表面が濃緑色で中央が窪んでいる。裏面は黄緑を帯びて中央のくぼみに白色の気孔帯がある。 The above-mentioned Koyamaki is an evergreen tree, the trunk is upright, the tree height is 35 to 40 m, the bark is torn from grayish brown to reddish brown, and peels off in a scaly shape. In addition, the long-leaved scale leaves are spirally alternated, and the short-branch leaves are rotified or bundled with linear 20 to 40 leaves joined by two leaves. Linear leaves have a dark green surface and a depressed center. The back side is yellowish green with a white pore in the center.
また、長さ６〜１２ｃｍ、幅は２〜４ｃｍの花は、３〜４月に咲き、雄花は楕円形で２０〜３０個が頭状に集合し、球果は円筒状楕円形で翌年の秋に熟すものである。 Also, 6-12 cm long and 2-4 cm wide flowers bloom in March-April, male flowers are oval and 20-30 are gathered in a head shape, and cones are cylindrical oval and the next year. It ripens in the fall.
この種は、日本固有種であって本州（福島県以南）、四国、九州に広く分布しており、これらの地域から入手が可能である。コウヤマキの樹木は高級建材物として用いられており、浴槽や風呂桶などでも使用されている。特に抗菌性に対する作用は知られているが、抗酸化作用、美白作用、抗老化作用及び抗炎症作用を有するとの知見はない。 This species is endemic to Japan and is widely distributed in Honshu (south of Fukushima Prefecture), Shikoku, and Kyushu, and is available from these regions. Kouyamaki trees are used as high-grade building materials, and are also used in bathtubs and bath tubs. In particular, the antibacterial action is known, but there is no knowledge that it has an antioxidant action, a whitening action, an anti-aging action and an anti-inflammatory action.
上記抽出原料として使用し得るコウヤマキの抽出部位としては、特に制限されることなく、例えば、地上部、根部又はこれらの混合部を使用することができるが、これらのうち地上部を用いるのが生産効率を高めるためにも好ましい。上記地上部としては、葉部、枝部、樹皮部、茎部、果実部等を用いるのが好ましく、特に葉部を用いるのが好ましい。 The extraction part of Kouyamaki that can be used as the raw material for extraction is not particularly limited, and for example, the above-ground part, root part, or mixed part thereof can be used. It is also preferable for increasing the efficiency. As the above-mentioned ground part, it is preferable to use a leaf part, a branch part, a bark part, a stem part, a fruit part, and the like, and it is particularly preferable to use a leaf part.
コウヤマキの有効成分に含有される活性酸素抑制物質、ラジカル消去物質、脂質酸化抑制物質、チロシナーゼ活性抑制物質、メラニン生成抑制物質、エラスターゼ活性抑制物質又はβ−ヘキソサミニダーゼ活性抑制作用物質の詳細な化学物質名は不明である。 Details of active oxygen inhibitory substance, radical scavenging substance, lipid oxidation inhibitory substance, tyrosinase activity inhibitory substance, melanin production inhibitory substance, elastase activity inhibitory substance or β-hexosaminidase activity inhibitory substance contained in the active ingredient of Kouyamaki The name of the chemical substance is unknown.
しかしながら、植物からの抽出操作に一般に用いられる水、水性溶媒または親水性有機溶媒を用いた抽出方法によって、コウヤマキの有効成分を得ることができ、これに活性酸素消去作用、ラジカル消去作用、脂質酸化抑制作用、チロシナーゼ活性抑制作用、メラニン生成抑制作用、エラスターゼ活性抑制作用又はβ−ヘキソサミニダーゼ活性抑制作用を有することが確認できる。 However, the active ingredients of Kouyamaki can be obtained by extraction methods using water, aqueous solvents or hydrophilic organic solvents, which are commonly used for extraction from plants, and this includes active oxygen scavenging action, radical scavenging action, lipid oxidation. It can be confirmed that it has an inhibitory action, a tyrosinase activity inhibitory action, a melanin production inhibitory action, an elastase activity inhibitory action, or a β-hexosaminidase activity inhibitory action.
例えば、コウヤマキを乾燥させた後、そのまま又は粗破砕機を用いて粉砕し、抽出溶媒による抽出に供することにより、上記作用を有する抽出物を得ることができる。乾燥は天日で行っても良いし、通常使用される乾燥機を用いて行っても良い。また、ヘキサン等の非極性溶媒によって脱脂等の前処理を施してから抽出原料として使用しても良い。脱脂等の前処理を行うことにより極性溶媒による抽出を効率よく行うことができる。 For example, after drying Koyamaki, the extract which has the said effect | action can be obtained by grind | pulverizing as it is or using a coarse crusher, and using for extraction by an extraction solvent. Drying may be performed in the sun or using a commonly used dryer. Further, after pretreatment such as degreasing with a nonpolar solvent such as hexane, it may be used as an extraction raw material. By performing a pretreatment such as degreasing, extraction with a polar solvent can be performed efficiently.
抽出溶媒としては、極性溶媒を用いるのが好ましく、例えば水、水性溶媒、親水性有機溶媒等が挙げられ、これらを単独又は２種以上組み合わせて、室温又は溶媒の沸点以下の温度で抽出することが好ましい。 As the extraction solvent, it is preferable to use a polar solvent, and examples thereof include water, an aqueous solvent, a hydrophilic organic solvent, and the like. Is preferred.
抽出溶媒として使用し得る水は、純水、水道水、井戸水、鉱泉水、鉱水、温泉水、湧水、淡水等の他にも、これらに各種処理を施したものが含まれる。水に施す処理としては、例えば、精製、加熱、殺菌、濾過、イオン交換、浸透圧調整、緩衝化等が含まれる。従って、この発明において抽出溶媒として使用し得る水には、精製水、熱水、イオン交換水、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水、超臨界水、亜臨界水等も含まれる。
また、水性溶媒とは、このような水に親水性有機溶媒以外の物質（たとえば食塩など水溶性塩類など）が、抽出溶媒としての性質を失わない濃度で溶解している水溶液をいう。
In addition to pure water, tap water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, water that can be used as the extraction solvent includes those subjected to various treatments. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, osmotic pressure adjustment, buffering, and the like. Therefore, the water that can be used as the extraction solvent in the present invention includes purified water, hot water, ion-exchanged water, physiological saline, phosphate buffer, phosphate buffered saline, supercritical water, subcritical water, and the like. included.
The aqueous solvent refers to an aqueous solution in which a substance other than the hydrophilic organic solvent (for example, water-soluble salts such as sodium chloride) is dissolved in such water at a concentration that does not lose the properties as an extraction solvent.
抽出溶媒として使用することのできる親水性有機溶媒としては、メタノール、エタノール、プロピルアルコール、イソプロピルアルコール等の炭素数１〜５の低級脂肪族アルコール；アセトン、メチルエチルケトン等の低級脂肪族ケトン；１，３−ブチレングリコール、プロピレングリコール、グリセリン等の炭素数２〜５の多価アルコール等が挙げられる。 Examples of hydrophilic organic solvents that can be used as the extraction solvent include lower aliphatic alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol, and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; -C2-C5 polyhydric alcohols, such as butylene glycol, propylene glycol, and glycerol, etc. are mentioned.
上記した２種以上の極性溶媒の混合液を抽出溶媒として使用する場合、その混合比は、適宜調整することができる。例えば、水と親水性有機溶媒である低級脂肪族アルコールとの混合液を使用する場合には、水１０質量部に対して低級脂肪族アルコール１〜９０質量部を混合することが好ましく、水と低級脂肪族ケトンとの混合液を使用する場合には、水１０質量部に対して低級脂肪族ケトン１〜４０質量部を混合することが好ましく、水と多価アルコールとの混合液を使用する場合には、水１０質量部に対して多価アルコール１〜９０質量部を混合することが好ましい。 When the above-mentioned mixed solution of two or more polar solvents is used as the extraction solvent, the mixing ratio can be adjusted as appropriate. For example, when using a mixed solution of water and a lower aliphatic alcohol which is a hydrophilic organic solvent, it is preferable to mix 1 to 90 parts by weight of a lower aliphatic alcohol with respect to 10 parts by weight of water, When using a mixed liquid with a lower aliphatic ketone, it is preferable to mix 1 to 40 parts by weight of a lower aliphatic ketone with respect to 10 parts by weight of water, and a mixed liquid of water and a polyhydric alcohol is used. In this case, it is preferable to mix 1 to 90 parts by mass of polyhydric alcohol with respect to 10 parts by mass of water.
抽出処理は、抽出原料に含まれる可溶性成分を抽出溶媒に溶出させ得る限り特に限定はされず、常法に従って行うことができる。例えば、抽出原料の５〜１５倍量（質量比）の抽出溶媒に、抽出原料を浸漬し、常温、還流加熱、超臨界又は亜臨界下で可溶性成分を抽出させた後、濾過して抽出残渣を除去することにより抽出液を得ることができる。得られた抽出液は、常法に従って希釈、濃縮、乾燥、精製等の処理を施してもよく、それぞれ抽出液の濃縮液、乾燥物、これらの粗精製物または精製物を得る。 The extraction treatment is not particularly limited as long as the soluble component contained in the extraction raw material can be eluted in the extraction solvent, and can be performed according to a conventional method. For example, the extraction raw material is immersed in an extraction solvent in an amount 5 to 15 times (mass ratio) of the extraction raw material, and the soluble component is extracted at room temperature, reflux heating, supercritical or subcritical, and then filtered to obtain an extraction residue. An extract can be obtained by removing. The obtained extract may be subjected to treatments such as dilution, concentration, drying, and purification according to a conventional method, and a concentrated solution, a dried product, and a crude or purified product thereof are obtained.
精製は、例えば、活性炭処理、吸着樹脂処理、イオン交換樹脂処理等により行うことができる。得られた抽出液はそのままでも抗酸化剤の有効成分として使用することができるが、濃縮液又は乾燥物としてもよい。 Purification can be performed by, for example, activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, or the like. The obtained extract can be used as it is as an active ingredient of an antioxidant, but it may be a concentrated solution or a dried product.
ここで、コウヤマキの有効成分の有する抗酸化作用について、より具体的な作用例を挙げると、例えば活性酸素消去作用、ラジカル消去作用及び／又は脂質酸化抑制作用であり、特にこれらに限定されるものではない。ここで、「活性酸素」には、スーパーオキサイド、過酸化水素、ヒドロキシラジカル、一重項酸素又は過酸化脂質等が含まれる。また、「ラジカル」とは、不対電子を１つ又はそれ以上有する分子又は原子を意味し、スーパーオキサイド、ヒドロキシラジカル、ＤＰＰＨ等が含まれる。 Here, with regard to the antioxidant action of the active ingredient of Kouyamaki, more specific action examples are exemplified, for example, active oxygen scavenging action, radical scavenging action and / or lipid oxidation inhibiting action, which are particularly limited to these. is not. Here, “active oxygen” includes superoxide, hydrogen peroxide, hydroxy radical, singlet oxygen, lipid peroxide, and the like. The “radical” means a molecule or atom having one or more unpaired electrons, and includes superoxide, hydroxy radical, DPPH and the like.
さらに、コウヤマキの有効成分が有する美白作用について、そのより具体的な作用は、例えば、チロシナーゼ活性抑制作用及び／又はメラニン生成抑制作用であるが、特にこれらの具体的作用に限定されるものではない。 Further, with regard to the whitening action of the active ingredient of Koyamaki, the more specific action is, for example, the tyrosinase activity inhibitory action and / or the melanin production inhibitory action, but is not particularly limited to these specific actions. .
さらにまた、コウヤマキの有効成分が有する抗老化作用について、より具体的な作用は、例えば、エラスターゼ活性抑制作用であるが、特にこれらの具体的作用に限定されるものではない。 Furthermore, for the anti-aging action of the active ingredient of Koyamaki, a more specific action is, for example, an elastase activity suppressing action, but is not particularly limited to these specific actions.
また、コウヤマキの有効成分が有する抗炎症作用について、より具体的な作用を挙げると、例えばβ−ヘキソサミニダーゼ活性抑制作用であるが、特にこれらの具体的作用に限定されるものではない。 Further, the anti-inflammatory action possessed by the active ingredient of Kouyamaki is more specifically, for example, β-hexosaminidase activity suppressing action, but is not particularly limited to these specific actions.
なお、上記コウヤマキの有効成分が有する活性酸素消去作用、ラジカル消去作用、脂質酸化抑制作用、チロシナーゼ活性抑制作用、メラニン生成抑制作用、エラスターゼ活性抑制作用又はβ−ヘキソサミニダーゼ活性抑制作用を利用し、活性酸素消去剤、ラジカル消去剤、脂質酸化抑制剤、チロシナーゼ活性抑制剤、メラニン生成抑制剤、エラスターゼ活性抑制剤又は抗炎症剤として使用してもよい。 In addition, the active oxygen scavenging action, radical scavenging action, lipid oxidation inhibitory action, tyrosinase activity inhibitory action, melanin production inhibitory action, elastase activity inhibitory action or β-hexosaminidase activity inhibitory action possessed by the active ingredient of Kouyamaki is used. , Active oxygen scavengers, radical scavengers, lipid oxidation inhibitors, tyrosinase activity inhibitors, melanin production inhibitors, elastase activity inhibitors or anti-inflammatory agents.
この発明の抗酸化剤 、美白剤、抗老化剤又は抗炎症剤は、上記コウヤマキの有効成分のみからなるものであってもよいし、上記有効成分から製剤化したものであってもよい。 The antioxidant, whitening agent, anti-aging agent, or anti-inflammatory agent of the present invention may be composed of only the active ingredient of Kouyamaki or may be formulated from the active ingredient.
上記コウヤマキの有効成分は、デキストリン、シクロデキストリン等の薬学的に許容し得るキャリアーその他任意の助剤を用いて、常法に従い、粉末状、顆粒状、液状等の任意の剤形に製剤化して提供することができ、他の組成物（例えば、後述する皮膚化粧料等）に配合して使用することができるほか、軟膏剤、外用液剤、貼付剤等として使用することができる。この際、助剤としては、例えば、賦形剤、結合剤、崩壊剤、滑沢剤、安定剤、矯臭剤等を用いることができる。 The above-mentioned active ingredient of Kouyamaki is formulated into any dosage form such as powder, granule, liquid etc. according to a conventional method using a pharmaceutically acceptable carrier such as dextrin and cyclodextrin and any other auxiliary agent. In addition to being able to be used by blending with other compositions (for example, skin cosmetics to be described later), it can be used as an ointment, a liquid for external use, a patch and the like. In this case, as an auxiliary agent, for example, an excipient, a binder, a disintegrant, a lubricant, a stabilizer, a flavoring agent and the like can be used.
この発明の抗酸化剤は、コウヤマキの有効成分が有する活性酸素消去作用、ラジカル消去作用及び／又は脂質酸化抑制作用を通じて、過剰に産生された活性酸素や生体内ラジカルを消去することができる。その結果、シワ、キメの消失、皮膚の弾力低下等の皮膚の老化を予防、治療又は改善することができる。ただし、この発明の抗酸化剤 はこれらの用途以外にも、活性酸素消去作用、ラジカル消去作用及び／又は脂質酸化抑制作用を発揮することに意義のあるすべての用途に用いることができる。 The antioxidant of this invention can eliminate the excessively produced active oxygen and in-vivo radicals through the active oxygen scavenging action, radical scavenging action and / or lipid oxidation inhibiting action of the active ingredient of Koyamaki. As a result, it is possible to prevent, treat, or improve skin aging such as wrinkles, disappearance of texture, and skin elasticity. However, the antioxidant of the present invention can be used for all purposes other than these uses, which are meaningful to exhibit an active oxygen scavenging action, radical scavenging action and / or lipid oxidation inhibiting action.
また、この発明の美白剤は、コウヤマキの有効成分が有するチロシナーゼ活性抑制作用及び／又はメラニン生成抑制作用を通じて、皮膚の黒化やシミ等を予防、治療又は改善することができる。ただし、この発明の美白剤はこれらの用途以外にも、チロシナーゼ活性抑制作用及び／又はメラニン生成抑制作用を発揮することに意義のあるすべての用途に用いることができる。 The whitening agent of the present invention can prevent, treat, or improve skin darkening, spots, etc. through the tyrosinase activity inhibitory action and / or the melanin production inhibitory action of the active ingredient of Kouyamaki. However, the whitening agent of the present invention can be used for all uses other than these uses, which are meaningful for exhibiting a tyrosinase activity inhibitory action and / or a melanin production inhibitory action.
さらに、この発明の抗老化剤は、コウヤマキの有効成分が有するエラスターゼ活性抑制作用を通じて、線維芽細胞由来のエラスターゼが必要以上にエラスチンを分解することを抑制することができる。その結果、シワ、キメの消失、皮膚の弾力低下等の皮膚の老化を予防、治療又は改善することができる。ただし、この発明の抗老化剤はこれらの用途以外にも、エラスターゼ活性抑制作用を発揮することに意義のあるすべての用途に用いることができる。 Furthermore, the anti-aging agent of this invention can suppress that the elastase derived from fibroblasts decomposes | disassembles elastin more than necessary through the elastase activity inhibitory action which the active ingredient of Kouyamaki has. As a result, it is possible to prevent, treat, or improve skin aging such as wrinkles, disappearance of texture, and skin elasticity. However, the anti-aging agent of this invention can be used for all uses other than these uses, which are meaningful for exerting an elastase activity inhibitory action.
さらに、この発明の抗炎症剤は、コウヤマキの有効成分が有するβ−ヘキソサミニダーゼ活性抑制作用を通じて、ヒスタミンと共に放出されるβ−ヘキソサミニダーゼの活性を抑制することができる。その結果、ヒスタミン遊離を阻害又は抑制する物質によりアレルギー性疾患等を予防・改善することができる。
ただし、この発明の抗炎症剤はこれらの用途以外にも、抗炎症作用を発揮することに意義のあるすべての用途に用いることができる。
Furthermore, the anti-inflammatory agent of this invention can suppress the activity of β-hexosaminidase released together with histamine through the β-hexosaminidase activity suppressing action of the active ingredient of Koyamaki. As a result, allergic diseases and the like can be prevented and improved by substances that inhibit or suppress histamine release.
However, the anti-inflammatory agent of this invention can be used for all uses other than these uses that are meaningful for exerting an anti-inflammatory action.
〔皮膚化粧料〕
上記コウヤマキからの抽出物は、皮膚に適用した場合の使用感と安全性に優れているため、皮膚化粧料に配合するのに好適である。この場合、コウヤマキの抽出物をそのまま配合してもよいし、当該抽出物から製剤化した抗酸化剤 、美白剤、抗老化剤又は抗炎症剤を配合してもよい。
[Skin cosmetic]
The extract from Kouyamaki is excellent in usability and safety when applied to the skin, and is therefore suitable for blending into skin cosmetics. In this case, an extract of Kouyamaki may be blended as it is, or an antioxidant, a whitening agent, an anti-aging agent or an anti-inflammatory agent formulated from the extract may be blended.
上記コウヤマキの抽出物を配合し得る皮膚化粧料としては、特に限定されるものではなく、例えば乳液、石鹸、洗顔料、入浴剤、クリーム、化粧水、オーデコロン、髭剃り用クリーム、髭剃り用ローション、化粧油、日焼け止めローション、おしろいパウダー、ファンデーション、香水、パック、爪クリーム、エナメル、エナメル除去液、眉墨、ほお紅、アイクリーム、アイシャドー、マスカラ、アイライナー口紅、リップクリーム、シャンプー、リンス、染毛料、分散液、洗浄料等が挙げられる。 Skin cosmetics that can be blended with the Kouyamaki extract are not particularly limited. For example, milky lotion, soap, facial cleanser, bath preparation, cream, lotion, eau de cologne, shaving cream, shaving lotion. , Cosmetic oil, sunscreen lotion, funny powder, foundation, perfume, pack, nail cream, enamel, enamel remover, eyebrow, blusher, eye cream, eye shadow, mascara, eyeliner lipstick, lip balm, shampoo, rinse, dye Examples thereof include hairs, dispersions, and cleaning materials.
上記コウヤマキの抽出物を皮膚化粧料に配合する場合、その配合量は、皮膚化粧料の種類等によって所期した作用が充分に得られるように適宜調整することができるが、有効成分として効率よく作用する好適な配合率は、標準的な抽出物（乾燥物）に換算して約０．０００１〜１０質量％であり、特に好適な配合率は、標準的な抽出物（乾燥物）に換算して約０．００１〜１質量％である。 When blending the above extract of Koyamaki into skin cosmetics, the blending amount can be adjusted as appropriate depending on the type of skin cosmetics, etc., so that the desired action can be sufficiently obtained. A suitable blending ratio that acts is about 0.0001 to 10% by mass in terms of a standard extract (dry matter), and a particularly suitable blending ratio is in terms of a standard extract (dry matter). And about 0.001 to 1% by mass.
また、この発明の皮膚外用剤には、上記必須成分のほかこの発明の効果を損なわない範囲内であれば、化粧品、医薬部外品などの皮膚外用剤に配合される成分、油分、高級アルコール、脂肪酸、紫外線吸収剤、粉体、顔料、界面活性剤、多価アルコール、糖、多糖、アミノ酸、ペプチド、タンパク質、高分子化合物、生理活性成分、溶媒、酸化防止剤、香料、防腐剤等を配合することができる。 In addition to the above essential components, the skin external preparation of the present invention, as long as the effects of the present invention are not impaired, are incorporated into skin external preparations such as cosmetics and quasi drugs, oils, higher alcohols , Fatty acids, UV absorbers, powders, pigments, surfactants, polyhydric alcohols, sugars, polysaccharides, amino acids, peptides, proteins, polymer compounds, bioactive ingredients, solvents, antioxidants, fragrances, preservatives, etc. Can be blended.
上記溶媒としては、水、エタノール、低級アルコール、エーテル類、ＬＰＧ、フルオロカーボン、Ｎ−メチルピロリドン、フルオロアルコール、揮発性直鎖状シリコーン、次世代フロン等が挙げられる。 Examples of the solvent include water, ethanol, lower alcohol, ethers, LPG, fluorocarbon, N-methylpyrrolidone, fluoroalcohol, volatile linear silicone, and next-generation fluorocarbon.
なお、この発明の抗酸化剤、美白剤、抗老化剤、抗炎症剤及び化粧料等の皮膚外用剤は、ヒトに対して適用される他、ヒト以外の動物（愛玩動物、家畜など）に対しても適用できる。 In addition, the external preparations for skin of the present invention, such as antioxidants, whitening agents, anti-aging agents, anti-inflammatory agents, and cosmetics, are applied to humans and are applied to animals other than humans (companion animals, domestic animals, etc.). It can also be applied to.
以下に、化粧品などの皮膚外用剤の製造例、試験例及び配合例を説明する。
〔製造例１〕
細切りにしたコウヤマキの地上部の乾燥物２００ｇに、下記の表１に示す抽出溶媒２０００ｇを加え、還流抽出器で５０℃の温度条件下にて２時間加熱抽出し、熱時濾過した。
濾過後の残渣について、さらに同様の抽出処理を行ない、得られた各抽出液を合わせて減圧下に濃縮し、さらに乾燥してコウヤマキ抽出物（乾燥物）を得た。抽出溶媒としては、水、３０質量％エタノール（水とエタノールとの質量比７：３の混合物）及び７０質量％エタノール（水とエタノールとの質量比３：７の混合物）を用いたときの各抽出物の収率を表１中に併記した。
Below, the manufacture example, test example, and compounding example of skin external preparations, such as cosmetics, are demonstrated.
[Production Example 1]
2000 g of the extraction solvent shown in Table 1 below was added to 200 g of the dried portion of the above ground portion of Koyamaki, which was chopped, and heated and extracted with a reflux extractor at 50 ° C. for 2 hours, followed by hot filtration.
The residue after filtration was further subjected to the same extraction treatment, and the obtained extracts were combined, concentrated under reduced pressure, and further dried to obtain a Koyamaki extract (dried product). As the extraction solvent, water, 30% by mass ethanol (a mixture of water and ethanol in a mass ratio of 7: 3) and 70% by mass ethanol (a mixture of water and ethanol in a mass ratio of 3: 7) are used. The yield of the extract is also shown in Table 1.
＜ＳＯＤ様活性試験＞
試料２のコウヤマキ抽出液を用い、活性酸素の一つであるスーパーオキサイドを消去するsuperoxide dismutase（ＳＯＤ）様活性試験を行なった。試験には同仁化学研究所製のＳＯＤ Ａｓｓａｙ Ｋｉｔ−ＷＳＴを用いた。
<SOD-like activity test>
A superoxide dismutase (SOD) -like activity test for eliminating superoxide, which is one of active oxygens, was performed using the Kouyamaki extract of Sample 2. For the test, SOD Assay Kit-WST manufactured by Dojindo Laboratories was used.
活性酸素の一つであるスーパーオキサイドを消去するsuperoxide dismutase（SOD）は以下の化１に示すスーパーオキサイドの不均化反応を触媒する酵素である。 Superoxide dismutase (SOD), which eliminates superoxide, which is one of active oxygens, is an enzyme that catalyzes the disproportionation reaction of superoxide shown in Chemical Formula 1 below.
試験方法としては、上記反応に比例反応するテトラゾリウム塩を用いたWST-1解析により、WST-1が分解されて生じたフォルマザン（formazan）を色素量として吸光度計によって解析し、その極大吸収である４５０ｎｍの増加を指標としてＳＯＤ様活性を評価した。 As a test method, WST-1 analysis using a tetrazolium salt proportional to the above reaction was conducted, and formazan generated by decomposition of WST-1 was analyzed with an absorptiometer as the amount of dye, and the maximum absorption was obtained. SOD-like activity was evaluated using an increase of 450 nm as an index.
コウヤマキ抽出液（試料２）は希釈用緩衝液（Dilution buffer）により希釈し、試料とした。スーパーオキシドラジカル中に試料を添加し、４５０ｎｍでの吸光度により測定した。その結果を下記の式で示されるＳＯＤ様活性率として表２に示した。 Kouyamaki extract (sample 2) was diluted with a dilution buffer to prepare a sample. Samples were added into the superoxide radical and measured by absorbance at 450 nm. The results are shown in Table 2 as the SOD-like activity rate represented by the following formula.
ＳＯＤ様活性率（％）＝｛１−（Ａ−Ｂ）/（Ｃ−Ｄ）｝×１００
（式中、Ａ、Ｂ、Ｃ、Ｄは以下の測定値を示す。Ａ：各濃度の試料溶液における反応溶液の吸光度、Ｂ：各濃度の試料溶液における調整溶液の吸光度、Ｃ：試料無添加における反応溶液の吸光度、Ｄ：試料無添加における調整溶液の吸光度）
SOD-like activity rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A, B, C and D represent the following measured values. A: Absorbance of the reaction solution in the sample solution of each concentration, B: Absorbance of the adjustment solution in the sample solution of each concentration, C: No sample added Absorbance of reaction solution in D, D: Absorbance of adjustment solution without addition of sample)
表２に示すように、コウヤマキ抽出液（試料２）は、優れた活性酸素消去作用を有することが確認された。また、活性酸素消去作用の程度は、コウヤマキ抽出液の濃度によって調節できることが確認された。 As shown in Table 2, it was confirmed that Kouyamaki extract (sample 2) has an excellent active oxygen scavenging action. Moreover, it was confirmed that the degree of the active oxygen scavenging action can be adjusted by the concentration of Kouyamaki extract.
＜ラジカル消去作用試験＞
製造例１で得られたコウヤマキ抽出液（試料２）について、１，１−ジフェニル-２-ピクリル-ヒドラジル（1,1-diphenyl-2-picryl-hydrazyl：以下、ＤＰＰＨ）を用いたラジカル消去作用試験を行なった。
<Radical scavenging action test>
Radical scavenging action using 1,1-diphenyl-2-picryl-hydrazyl (hereinafter referred to as DPPH) for Kouyamaki extract (Sample 2) obtained in Production Example 1 A test was conducted.
試料２のコウヤマキ抽出液を用い、５２０ｎｍに極大吸収を持つ安定なラジカル物質であるＤＰＰＨがコウヤマキ抽出物に含まれる抗酸化物質により還元されることで生じる５２０ｎｍにおける吸光度の減少を捕らえて抗酸化能を評価した。 Using the Kouyamaki extract of Sample 2, the ability of antioxidants to capture the decrease in absorbance at 520 nm caused by the reduction of DPPH, which is a stable radical substance having a maximum absorption at 520 nm, with the antioxidant contained in Kouyamaki extract Evaluated.
因みに、ヒトはヒドロキシラジカルを消去する酵素を産生していないため、皮膚等で産生されたヒドロキシラジカルの消去作用を有する物質を配合した化粧料を塗布することにより様々な皮膚疾患を予防及び改善できる。 By the way, since humans do not produce enzymes that scavenge hydroxy radicals, various skin diseases can be prevented and ameliorated by applying cosmetics containing substances that have a scavenging action on hydroxy radicals produced in the skin, etc. .
コウヤマキ抽出液（試料２）はエタノールに希釈し、試料とした。試料を９６穴プレートに入れ、５×１０−４ mol/LのDPPH溶液を加えて２５℃、３０分間反応させ、５２０ｎｍの吸光度を測定した。その結果を下記の式に示すＤＰＰＨラジカル消去率として表３に示した。 Kouyamaki extract (sample 2) was diluted in ethanol and used as a sample. The sample was put in a 96-well plate, 5 × 10 −4 mol / L DPPH solution was added, and the mixture was reacted at 25 ° C. for 30 minutes, and the absorbance at 520 nm was measured. The results are shown in Table 3 as the DPPH radical scavenging rate shown in the following formula.
ＤＰＰＨラジカル消去率（％）＝｛１−（Ａ−Ｂ）/（Ｃ−Ｄ）｝×１００
（式中、Ａ、Ｂ、Ｃ、Ｄは以下の測定値を示す。Ａ：各濃度の試料溶液における反応溶液の吸光度、Ｂ：各濃度の試料溶液における調整溶液の吸光度、Ｃ：試料無添加における反応溶液の吸光度、Ｄ：試料無添加における調整溶液の吸光度）
DPPH radical scavenging rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A, B, C and D represent the following measured values. A: Absorbance of the reaction solution in the sample solution of each concentration, B: Absorbance of the adjustment solution in the sample solution of each concentration, C: No sample added Absorbance of reaction solution in D, D: Absorbance of adjustment solution without addition of sample)
表３に示すように、コウヤマキ抽出液（試料２）は、優れたラジカル消去作用を有することが確認された。 As shown in Table 3, it was confirmed that Kouyamaki extract (sample 2) has an excellent radical scavenging action.
＜脂質酸化抑制試験＞
製造例１で得られたコウヤマキ抽出液（試料２）を用いて、リノール酸を用いた脂質酸化抑制試験を行なった。
<Lipid oxidation inhibition test>
A lipid oxidation inhibition test using linoleic acid was performed using the Kouyamaki extract (sample 2) obtained in Production Example 1.
皮膚には皮脂など多量の不飽和脂肪酸が存在し、活性酸素等により酸化され過酸化脂質となる。過酸化脂質が細胞へ障害を与えることにより、炎症や色素沈着等による皮膚老化の原因と考えられている。脂質過酸化抑制作用により、過酸化脂質による皮膚に対する障害を軽減できると考えられた。 The skin contains a large amount of unsaturated fatty acids such as sebum and is oxidized by active oxygen or the like to become lipid peroxides. It is considered that lipid peroxide damages cells, causing skin aging due to inflammation, pigmentation, and the like. It was considered that the lipid peroxidation inhibitory action can reduce the damage to the skin caused by lipid peroxide.
リノール酸は、９、１２位にシス二重結合を持ち、非常に水素ラジカルが抜けやすい状態の物質である。これにより、脂質ヒドロペルオキシドを自動酸化によって生成させてしまうので、酸化防止剤の検証試験として利用される。 Linoleic acid has a cis double bond at the 9th and 12th positions, and is a substance in a state where hydrogen radicals are very easily removed. As a result, lipid hydroperoxide is generated by auto-oxidation and is used as a verification test for antioxidants.
試験方法としては、コウヤマキ抽出液（試料２）は超純水にて希釈し、試料とした。１０ｍＭリノール酸を調整し、試料を添加して４０℃にてインキュベート後、ロダン鉄法を用い４５０ｎｍでの吸光度により測定した。その結果を下記の式に示すリノール酸自動酸化抑制率として表４に示した。 As a test method, Koyamaki extract (sample 2) was diluted with ultrapure water to prepare a sample. 10 mM linoleic acid was prepared, a sample was added and incubated at 40 ° C., and then measured by absorbance at 450 nm using the rhodan iron method. The results are shown in Table 4 as the linoleic acid autooxidation inhibition rate shown in the following formula.
リノール酸自動酸化抑制率（％）＝｛１−（Ａ−Ｂ）/（Ｃ−Ｄ）｝×１００
（式中、Ａ、Ｂ、Ｃ、Ｄは以下の測定値を示す。Ａ:各濃度における４０℃反応時の吸光度、Ｂ：各濃度における４℃反応時の吸光度、Ｃ：試料無添加における４０℃反応時の吸光度、Ｄ：試料無添加における４℃反応時の吸光度）
Linoleic acid autooxidation inhibition rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A, B, C and D represent the following measured values. A: Absorbance at 40 ° C. reaction at each concentration, B: Absorbance at 4 ° C. reaction at each concentration, C: 40 without sample addition. Absorbance during reaction at ° C, D: Absorbance at 4 ° C reaction without addition of sample)
表４に示すように、コウヤマキ抽出液（試料２）は、優れた脂質酸化抑制作用を有することが確認された。 As shown in Table 4, it was confirmed that Kouyamaki extract (sample 2) has an excellent lipid oxidation inhibitory action.
＜チロシナーゼ活性抑制作用試験＞
製造例１で得られたコウヤマキ抽出液（試料２）を用いて、マッシュルーム由来チロシナーゼによるチロシナーゼ活性抑制作用試験を行なった。
<Tyrosinase activity inhibitory action test>
A tyrosinase activity inhibitory action test using mushroom-derived tyrosinase was performed using the Kouyamaki extract (sample 2) obtained in Production Example 1.
コウヤマキ抽出液（試料２）は、０．１Ｍのリン酸緩衝液（ｐＨ６．５）に希釈し、試料とした。０．１Ｍのリン酸緩衝液（ｐＨ６．５）０．７５ｍＬに、１０Ｍ L−ドーパ０．０５ｍｌを加え、さらにチロシナーゼ溶液（マッシュルーム由来，１５３Ｕ／ｍＬ，Sigma社製）０．１ｍＬを加えて、３７℃でインキュベーションした。１０分反応させたのち、波長４７５ｎｍにおける吸光度を測定した。同様の操作と吸光度測定で、酵素溶液を添加せずに０．１Ｍのリン酸緩衝液（ｐＨ６．５）についても行なった。さらに、試料溶液を添加せず、試料を溶解する溶媒のみについても同様の測定を行なった。得られた結果から、下記の式によりチロシナーゼ活性抑制率を算出した。この結果を下記の式に示すチロシナーゼ活性抑制率として表５に示した。 Kouyamaki extract (sample 2) was diluted with 0.1 M phosphate buffer (pH 6.5) to prepare a sample. To 0.75 mL of 0.1 M phosphate buffer (pH 6.5), 0.05 mL of 10M L-dopa was added, and 0.1 mL of tyrosinase solution (derived from mushroom, 153 U / mL, Sigma) was added, Incubated at 37 ° C. After reacting for 10 minutes, absorbance at a wavelength of 475 nm was measured. The same operation and absorbance measurement were performed for 0.1 M phosphate buffer (pH 6.5) without adding the enzyme solution. Furthermore, the same measurement was performed for only the solvent that dissolves the sample without adding the sample solution. From the obtained results, the tyrosinase activity inhibition rate was calculated by the following formula. The results are shown in Table 5 as the tyrosinase activity inhibition rate shown in the following formula.
チロシナーゼ活性抑制率(％)＝{１−(Ａ−Ｂ)／(Ｃ−Ｄ)}×１００
（式中、Ａは「酵素溶液添加、試料溶液添加時の吸光度」を、Ｂは「酵素溶液無添加、試料溶液添加時の吸光度」を、Ｃは「酵素溶液添加、試料溶液無添加時の吸光度」を、Ｄは「酵素溶液無添加、試料溶液無添加時の吸光度」を示す。）
Tyrosinase activity inhibition rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A is “absorbance when enzyme solution is added and sample solution is added”, B is “absorbance when enzyme solution is not added and sample solution is added”, and C is “absorbance when enzyme solution is added and sample solution is not added”. "Absorbance", D indicates "absorbance when no enzyme solution is added and no sample solution is added.")
表５に示すように、コウヤマキ抽出液（試料２）は、優れたチロシナーゼ活性抑制作用を有することが確認された。また、チロシナーゼ活性抑制作用の程度は、コウヤマキ抽出液の濃度によって調節できることが確認された。 As shown in Table 5, it was confirmed that Kouyamaki extract (sample 2) has an excellent tyrosinase activity inhibitory action. It was also confirmed that the degree of tyrosinase activity inhibitory action can be adjusted by the concentration of Kouyamaki extract.
＜メラニン生成抑制作用試験＞
製造例１で得られたコウヤマキ抽出液（試料２）を用いて、マウスメラノーマ細胞Ｂ１６によるメラニン生成抑制作用試験を行なった。
<Test for inhibiting melanin production>
Using the Koyamaki extract (sample 2) obtained in Production Example 1, a melanin production inhibitory action test using mouse melanoma cells B16 was performed.
試験方法としては、マウスメラノーマ細胞Ｂ１６を１０％ＦＢＳ含有ＭＥＭ培地中で培養したものを使用した。なおこの培養は全て３７℃、５％ＣＯ2存在下条件で行なった。コウヤマキ抽出液（試料２）は０．４５μｍフィルター滅菌後、１０％ＦＢＳ含有ＭＥＭ培地にて希釈し、試料とした。詳細には、５×１０4 ｃｅｌｌｓ／ｍｌのメラノーマ細胞Ｂ１６を、６０mmプラスティックシャーレに播種し、２４時間培養した。その後、新鮮な培地に交換し、試験試料を添加した。試料添加６０時間後、培地を除去し、細胞を０．８５Ｎ水酸化カリウム溶液で溶解させ、４０５ｎｍにおける吸光度を測定した。また、試料無添加の細胞のメラニン生成率を１００％として試料添加時のメラニン生成率を算出した。メラニン生成抑制率は、試料無添加のメラニン生成率（１００％）から試料添加時のメラニン生成率を差し引いたものとした。この結果をメラニン生成抑制率（％）として表６に示した。 As a test method, mouse melanoma cell B16 cultured in 10% FBS-containing MEM medium was used. This culture was all performed at 37 ° C. in the presence of 5% CO 2 . Kouyamaki extract (sample 2) was sterilized with a 0.45 μm filter and diluted with MEM medium containing 10% FBS to prepare a sample. Specifically, 5 × 10 4 cells / ml melanoma cells B16 were seeded in a 60 mm plastic petri dish and cultured for 24 hours. Then, it replaced | exchanged for the fresh culture medium and added the test sample. After 60 hours from the addition of the sample, the medium was removed, the cells were dissolved with 0.85N potassium hydroxide solution, and the absorbance at 405 nm was measured. Moreover, the melanin production rate at the time of sample addition was computed by making the melanin production rate of the cell without a sample 100%. The melanin production inhibition rate was obtained by subtracting the melanin production rate at the time of sample addition from the melanin production rate without sample addition (100%). The results are shown in Table 6 as the melanin production inhibition rate (%).
表６に示すように、コウヤマキ抽出液（試料２）は、優れたメラニン生成抑制作用を有することが確認された。また、メラニン生成抑制作用の程度は、コウヤマキ抽出液の濃度によって調節できることが確認された。 As shown in Table 6, it was confirmed that Kouyamaki extract (sample 2) has an excellent melanin production inhibitory action. Moreover, it was confirmed that the degree of the melanin production inhibitory effect can be adjusted by the concentration of Kouyamaki extract.
＜エラスターゼ活性抑制作用試験＞
製造例１で得られたコウヤマキ抽出液（試料２）を用いて、ブタ膵臓由来エラスターゼによるエラスターゼ活性抑制作用試験を行なった。
<Elastase activity inhibitory action test>
Using the Koyamaki extract (sample 2) obtained in Production Example 1, an elastase activity inhibitory action test by porcine pancreatic elastase was performed.
試験方法としては、人工基質であるN-succinyl-L-alanyl-L-alanyl-L-alaniline-p-nitroanilideはエラスターゼ存在化においてnitroanilideが遊離することにより黄色に呈色する。従って、このnitroanilideの極大吸収４０５ｎｍを用いて、エラスターゼ活性抑制を評価した。 As the test method, N-succinyl-L-alanyl-L-alanyl-L-alaniline-p-nitroanilide, which is an artificial substrate, turns yellow when nitroanilide is released in the presence of elastase. Therefore, elastase activity suppression was evaluated using the maximum absorption 405 nm of this nitroanilide.
コウヤマキ抽出液（試料２）は０．２ＭTris-HCl（ｐＨ８．０）に希釈し、試料とした。試料と酵素(エラスターゼ)共存下に基質を添加することにより基質がエラスターゼにより分解され発色するので、これを４０５ｎｍでの吸光度により測定した。この結果を下記の式に示すエラスターゼ活性抑制率として表７に示した。 Kouyamaki extract (sample 2) was diluted in 0.2M Tris-HCl (pH 8.0) to prepare a sample. When the substrate was added in the presence of the sample and the enzyme (elastase), the substrate was decomposed by elastase and colored, and this was measured by absorbance at 405 nm. The results are shown in Table 7 as the elastase activity inhibition rate shown in the following formula.
エラスターゼ活性抑制率（％）＝ ｛１−（Ａ−Ｂ）／（Ｃ−Ｄ）｝×１００
（式中、Ａは「酵素溶液添加、試料溶液添加時の吸光度」を、Ｂは「酵素溶液無添加、試料溶液添加時の吸光度」を、Ｃは「酵素溶液添加、試料溶液無添加時の吸光度」を、Ｄは「酵素溶液無添加、試料溶液無添加時の吸光度」を示す。）
Elastase activity inhibition rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A is “absorbance when enzyme solution is added and sample solution is added”, B is “absorbance when enzyme solution is not added and sample solution is added”, and C is “absorbance when enzyme solution is added and sample solution is not added”. "Absorbance", D indicates "absorbance when no enzyme solution is added and no sample solution is added.")
表７に示すように、コウヤマキ抽出液（試料２）は、優れたエラスターゼ活性抑制作用を有することが確認された。 As shown in Table 7, it was confirmed that Kouyamaki extract (sample 2) has an excellent elastase activity inhibitory action.
＜抗炎症作用試験＞
製造例１で得られたコウヤマキ抽出液（試料２）を用いて、ラット好塩基性白血病細胞ＲＢＬ−２Ｈ３による抗炎症作用試験を行なった。
<Anti-inflammatory test>
An anti-inflammatory activity test using rat basophilic leukemia cells RBL-2H3 was performed using the Kouyamaki extract (sample 2) obtained in Production Example 1.
抗原刺激によって惹起されたラット好塩基性白血病細胞ＲＢＬ−２Ｈ３の脱顆粒の際にヒスタミン等の化学物質と共に放出されるβ-ヘキソサミニダーゼの遊離量を測定することで脱顆粒の指標とした。 An index of degranulation was determined by measuring the amount of β-hexosaminidase released together with chemical substances such as histamine during degranulation of rat basophilic leukemia cells RBL-2H3 induced by antigen stimulation. .
コウヤマキ抽出液（試料２）は、０．４５μｍフィルター滅菌後、ＰＢＳに希釈し、試料とした。抗体により感作させた細胞に、試料を添加、抗原による脱顆粒刺激を行ない、その際ヒスタミンなどの化学物質と共に放出されるβ-ヘキソサミニダーゼを、基質を用いた反応系により呈色し４０５ｎｍにおける吸光度を測定した。この結果を下記の式に示すβ−ヘキソサミニダーゼ活性抑制率として表８に示した。 Kouyamaki extract (sample 2) was sterilized by 0.45 μm filter, diluted in PBS, and used as a sample. Samples are added to cells sensitized with antibodies, and degranulation is stimulated with antigen. At that time, β-hexosaminidase released together with chemical substances such as histamine is colored by a reaction system using a substrate. Absorbance at 405 nm was measured. The results are shown in Table 8 as the β-hexosaminidase activity inhibition rate shown in the following formula.
β−ヘキソサミニダーゼ活性抑制率（％）＝ {１−(Ａ−Ｂ)／(Ｃ−Ｄ)}×１００
（式中、Ａは「試料溶液添加時の吸光度」を、Ｂは「細胞非存在下での試料溶液添加時の吸光度」を、Ｃは「試料溶液無添加時の吸光度」を、Ｄは「細胞非存在下での試料溶液無添加時の吸光度」を示す。）
β-hexosaminidase activity inhibition rate (%) = {1− (A−B) / (C−D)} × 100
(In the formula, A is “absorbance when sample solution is added”, B is “absorbance when sample solution is added in the absence of cells”, C is “absorbance when sample solution is not added”, and D is “ Absorbance when no sample solution is added in the absence of cells ”.)
表８に示すように、コウヤマキ抽出液（試料２）は、優れた抗炎症作用を有することが確認された。また、抗炎症作用の程度は、コウヤマキ抽出液の濃度によって調節できることが確認された。 As shown in Table 8, it was confirmed that Kouyamaki extract (sample 2) has an excellent anti-inflammatory action. Moreover, it was confirmed that the degree of anti-inflammatory action can be adjusted by the concentration of Kouyamaki extract.
この発明の実施形態として皮膚外用剤（化粧料）の処方例を以下に列挙する。成分に続いて示す配合割合は、全て重量％である。
［処方例１；化粧水］
セチルアルコール ５
グリセリン ２
１，３−ブチレングリコール ５
トリメチルグリシン １
ポリアスパラギン酸ナトリウム ０．１
ポリオキシエチレンポリオキシプロピレンデシルテトラデシルエーテル ０．２５
α−トコフェロール ２−Ｌ−アスコルビン酸リン酸ジエステルカリウム ０．１
ＨＥＤＴＡ３ナトリウム ０．１
コウヤマキ抽出液（試料２）０．１
ヘキサメタリン酸ナトリウム ０．００３
カルボキシビニルポリマー ０．０５
水酸化カリウム ０．０２５
フェノキシエタノール 適量
精製水 残余
香料 適量
Formulation examples of the external preparation for skin (cosmetics) are listed below as embodiments of the present invention. The blending ratio shown following the ingredients is all in weight percent.
[Formulation Example 1; lotion]
Cetyl alcohol 5
Glycerin 2
1,3-butylene glycol 5
Trimethylglycine 1
Sodium polyaspartate 0.1
Polyoxyethylene polyoxypropylene decyl tetradecyl ether 0.25
α-tocopherol 2-L-ascorbic acid phosphate diester potassium 0.1
HEDTA3 sodium 0.1
Kouyamaki extract (sample 2) 0.1
Sodium hexametaphosphate 0.003
Carboxyvinyl polymer 0.05
Potassium hydroxide 0.025
Phenoxyethanol Appropriate amount Purified water Residual perfume Appropriate amount
［処方例２；化粧水］
グリセリン ２．５
１，３−ブチレングリコール ４
エリスリトール １．５
ポリオキシエチレンメチルグルコシド １
ポリオキシエチレン硬化ヒマシ油 ０．５
コウヤマキ抽出液（試料２） ０．１
クエン酸 ０．０２
クエン酸ナトリウム ０．０８
フェノキシエタノール 適量
精製水 残余
香料 適量
[Formulation Example 2; lotion]
Glycerin 2.5
1,3-butylene glycol 4
Erythritol 1.5
Polyoxyethylene methyl glucoside 1
Polyoxyethylene hydrogenated castor oil 0.5
Kouyamaki extract (sample 2) 0.1
Citric acid 0.02
Sodium citrate 0.08
Phenoxyethanol Appropriate amount Purified water Residual perfume Appropriate amount
［処方例３；乳液］
ジメチルポリシロキサン ２．５
デカメチルシクロペンタシロキサン ２３
ドデカメチルシクロヘキサシロキサン １５
ポリオキシエチレン・メチルポリシロキサン共重合体 １．５
トリメチルシロキシケイ酸 １
１，３−ブチレングリコール ５
スクワラン １．５
タルク ６
グリチルリチン酸ジカリウム ０．１
コウヤマキ抽出液（試料２） ０．１
酢酸トコフェロール ０．１
エデト酸三ナトリウム ０．０５
パラメトキシ桂皮酸２−エチルヘキシル ５
シリコーン被覆微粒子酸化チタン ４
ジメチルジステアリルアンモニウムヘクトライト ０．５
球状ポリエチレン末 ３
フェノキシエタノール 適量
精製水 残余
香料 適量
[Prescription Example 3; Emulsion]
Dimethylpolysiloxane 2.5
Decamethylcyclopentasiloxane 23
Dodecamethylcyclohexasiloxane 15
Polyoxyethylene / methylpolysiloxane copolymer 1.5
Trimethylsiloxysilicic acid 1
1,3-butylene glycol 5
Squalane 1.5
Talc 6
Dipotassium glycyrrhizinate 0.1
Kouyamaki extract (sample 2) 0.1
Tocopherol acetate 0.1
Edetate trisodium 0.05
2-methoxyhexyl paramethoxycinnamate 5
Silicone coated fine particle titanium oxide 4
Dimethyl distearyl ammonium hectorite 0.5
Spherical polyethylene powder 3
Phenoxyethanol Appropriate amount Purified water Residual perfume Appropriate amount
［処方例４；クリーム］
流動パラフィン ９
ワセリン ２
ジメチルポリシロキサン ２
ステアリルアルコール ４
ベヘニルアルコール ２
グリセリン ５
ジプロピレングリコール ４
キシリトール １
テトラ２−エチルヘキサン酸ペンタエリスリット ４
親油型モノステアリン酸グリセリン ２
モノイソステアリン酸ポリオキシエチレングリセリル ２
モノステアリン酸ポリオキシエチレングリセリン １
クエン酸 ０．０５
クエン酸ナトリウム ０．０５
水酸化ナトリウム ０．０１５
油溶性甘草エキス ０．１
酢酸トコフェロール ０．１
コウヤマキ抽出液（試料２） ０．１
パラオキシ安息香酸エステル 適量
フェノキシエタノール 適量
エデト酸三ナトリウム ０．０５
ポリビニルアルコール ０．５
ヒドロキシエチルセルロース ０．５
カルボキシビニルポリマー ０．０５
精製水 残余
香料 適量
[Prescription Example 4; Cream]
Liquid paraffin 9
Vaseline 2
Dimethylpolysiloxane 2
Stearyl alcohol 4
Behenyl alcohol 2
Glycerin 5
Dipropylene glycol 4
Xylitol 1
Tetra-2-ethylhexanoic acid pentaerythrit 4
Lipophilic glyceryl monostearate 2
Polyisoethylene glyceryl monoisostearate 2
Polyoxyethylene glyceryl monostearate 1
Citric acid 0.05
Sodium citrate 0.05
Sodium hydroxide 0.015
Oil-soluble licorice extract 0.1
Tocopherol acetate 0.1
Kouyamaki extract (sample 2) 0.1
P-Hydroxybenzoate appropriate amount phenoxyethanol appropriate amount edetate trisodium 0.05
Polyvinyl alcohol 0.5
Hydroxyethyl cellulose 0.5
Carboxyvinyl polymer 0.05
Purified water Residual fragrance
［処方例５；ジェル］
グリセリン ２
１，３−ブチレングリコール ４
水酸化ナトリウム ０．２
エデト酸三ナトリウム ０．０５
コウヤマキ抽出液（試料２） ０．１
カルボキシビニルポリマー ０．２５
パラオキシ安息香酸エステル 適量
精製水 残余
[Prescription Example 5; Gel]
Glycerin 2
1,3-butylene glycol 4
Sodium hydroxide 0.2
Edetate trisodium 0.05
Kouyamaki extract (sample 2) 0.1
Carboxyvinyl polymer 0.25
P-Hydroxybenzoate appropriate amount purified water remaining
［処方例６；乳化型ファンデーション］
ベヘニルアルコール ０．５
ジプロピレングリコール ６
ステアリン酸 １．５
モノステアリン酸グリセリン １
水酸化ナトリウム ０．１５
トリエタノールアミン ０．６
酢酸トコフェロール ０．１
パラオキシ安息香酸エステル 適量
黄酸化鉄 １
ジメチルポリシロキサン（６ｃｓ） ２
ジメチルポリシロキサン（１００ｃｓ） ５
ステアリルアルコール １．５
イソステアリン酸 １．５
ベヘニン酸 ０．５
２−エチルヘキサン酸セチル １０
モノステアリン酸ポリオキシエチレングリセリン １
酸化チタン ３
表面処理酸化チタン １０
ポリアクリル酸アルキル被覆雲母チタン ０．５
黒酸化鉄 適量
無水ケイ酸 ６
パラメトキシ桂皮酸２−エチルヘキシル ２
ベンガラ 適量
群青 適量
法定色素 適量
キサンタンガム ０．１
ベントナイト １
カルボキシメチルセルロース ０．１
コウヤマキ抽出液（試料２） ０．１
精製水 残余
香料 適量
[Prescription Example 6; Emulsification Foundation]
Behenyl alcohol 0.5
Dipropylene glycol 6
Stearic acid 1.5
Glycerol monostearate 1
Sodium hydroxide 0.15
Triethanolamine 0.6
Tocopherol acetate 0.1
P-Hydroxybenzoic acid ester Appropriate amount of yellow iron oxide 1
Dimethylpolysiloxane (6cs) 2
Dimethylpolysiloxane (100cs) 5
Stearyl alcohol 1.5
Isostearic acid 1.5
Behenic acid 0.5
Cetyl 2-ethylhexanoate 10
Polyoxyethylene glyceryl monostearate 1
Titanium oxide 3
Surface-treated titanium oxide 10
Polyalkyl acrylate coated mica titanium 0.5
Black iron oxide appropriate amount Silicic anhydride 6
2-methoxyhexyl paramethoxycinnamate 2
Bengala appropriate amount ultramarine blue appropriate amount legal dye appropriate amount xanthan gum 0.1
Bentonite 1
Carboxymethylcellulose 0.1
Kouyamaki extract (sample 2) 0.1
Purified water Residual fragrance
［処方例７；固形ファンデーション］
タルク ４３
カオリン １５
セリサイト １０
亜鉛 ７
酸化チタン ４
黄酸化鉄 ３
黒酸化鉄 適量
ベンガラ 適量
スクワラン ８
イソステアリン酸 4
モノオレイン酸ＰＯＥソルビタン ３
オクタン酸イソセチル ２
コウヤマキ抽出液（試料２） ０．５
パラオキシ安息香酸エステル 適量
香料 適量
[Prescription Example 7; Solid Foundation]
Talc 43
Kaolin 15
Sericite 10
Zinc 7
Titanium oxide 4
Yellow iron oxide 3
Black iron oxide Appropriate amount Bengala Appropriate amount Squalane 8
Isostearic acid 4
Monooleic acid POE sorbitan 3
Isocetyl octoate 2
Kouyamaki extract (sample 2) 0.5
P-Hydroxybenzoate ester
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006254537A JP4757157B2 (en) | 2006-09-20 | 2006-09-20 | Topical skin preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006254537A JP4757157B2 (en) | 2006-09-20 | 2006-09-20 | Topical skin preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008074748A true JP2008074748A (en) | 2008-04-03 |
| JP4757157B2 JP4757157B2 (en) | 2011-08-24 |
Family
ID=39347177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006254537A Active JP4757157B2 (en) | 2006-09-20 | 2006-09-20 | Topical skin preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4757157B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011213658A (en) * | 2010-03-31 | 2011-10-27 | Naris Cosmetics Co Ltd | Antioxidant, ultraviolet hazard inhibitor and anti-photoageing cosmetic |
| CN112807263A (en) * | 2021-03-01 | 2021-05-18 | 科丝美诗(中国)化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
| CN114668697A (en) * | 2022-05-05 | 2022-06-28 | 杭州浮力网络信息科技有限公司 | Essence water with antioxidant and anti-inflammatory effects |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206539A (en) * | 1982-05-27 | 1983-12-01 | Kuraray Co Ltd | Preparation of polyprenyl compound or its mixture |
| JPS63198693A (en) * | 1987-01-14 | 1988-08-17 | インデナ エス．ピー．エー． | Composite compound of bioflavonoid and phospholipid, its production and use and drug and cosmetics composition containing the same |
| JPH03167133A (en) * | 1989-10-27 | 1991-07-19 | Indena Spa | Composition for treating accumulation of fat in human body |
| JPH09263534A (en) * | 1996-03-29 | 1997-10-07 | Sunstar Inc | Promoter for melanogenesis |
| JP2006016383A (en) * | 2004-05-31 | 2006-01-19 | Showa Denko Kk | Skin care preparation for slender body and cosmetic comprising the same |
| JP2007008900A (en) * | 2005-07-04 | 2007-01-18 | Bio Yakuhin Kk | Hair growth promoter containing biflavones as active component |
| JP2007022933A (en) * | 2005-07-13 | 2007-02-01 | Yoko Takeuchi | Oral cavity composition for prevention and removal of dental plaque, prevention and dissolution of dental calculus, and prevention and treatment of periodontal disease |
-
2006
- 2006-09-20 JP JP2006254537A patent/JP4757157B2/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58206539A (en) * | 1982-05-27 | 1983-12-01 | Kuraray Co Ltd | Preparation of polyprenyl compound or its mixture |
| JPS63198693A (en) * | 1987-01-14 | 1988-08-17 | インデナ エス．ピー．エー． | Composite compound of bioflavonoid and phospholipid, its production and use and drug and cosmetics composition containing the same |
| JPH03167133A (en) * | 1989-10-27 | 1991-07-19 | Indena Spa | Composition for treating accumulation of fat in human body |
| JPH09263534A (en) * | 1996-03-29 | 1997-10-07 | Sunstar Inc | Promoter for melanogenesis |
| JP2006016383A (en) * | 2004-05-31 | 2006-01-19 | Showa Denko Kk | Skin care preparation for slender body and cosmetic comprising the same |
| JP2007008900A (en) * | 2005-07-04 | 2007-01-18 | Bio Yakuhin Kk | Hair growth promoter containing biflavones as active component |
| JP2007022933A (en) * | 2005-07-13 | 2007-02-01 | Yoko Takeuchi | Oral cavity composition for prevention and removal of dental plaque, prevention and dissolution of dental calculus, and prevention and treatment of periodontal disease |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011213658A (en) * | 2010-03-31 | 2011-10-27 | Naris Cosmetics Co Ltd | Antioxidant, ultraviolet hazard inhibitor and anti-photoageing cosmetic |
| CN112807263A (en) * | 2021-03-01 | 2021-05-18 | 科丝美诗(中国)化妆品有限公司 | Anti-aging composition and preparation method and application thereof |
| CN114668697A (en) * | 2022-05-05 | 2022-06-28 | 杭州浮力网络信息科技有限公司 | Essence water with antioxidant and anti-inflammatory effects |
| CN114668697B (en) * | 2022-05-05 | 2024-03-15 | 广州市比柔生物科技有限公司 | Essence water with antioxidant and anti-inflammatory effects |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4757157B2 (en) | 2011-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4176912B2 (en) | Cosmetic composition containing moisturizing plant extract | |
| JP2010006708A (en) | External preparation for skin, bleaching agent, anti-aging agent and anti-oxidizing agent | |
| JP2006008566A (en) | Cosmetic agent containing lactic acid bacteria fermentation product of fruit juice as active ingredient and its application | |
| JP2006188463A (en) | Melanin-formation inhibitor and cosmetic composition comprising the same | |
| JP5550839B2 (en) | Whitening agent | |
| KR20190028996A (en) | Cosmetic composition for protecting skin from UV which comprises extract of bitter ground, persimmon leaf and ceramium kondoi | |
| JP2001335499A (en) | Cosmetic composition | |
| JP4033808B2 (en) | Beauty / health material containing Himefuuro extract | |
| JP2006124356A (en) | INTERLEUKIN-1alpha PRODUCTION INHIBITOR | |
| JP2005089355A (en) | Isomaltooligosaccharide-containing ameliorant for indigenous skin bacterial flora | |
| KR101639578B1 (en) | Cosmetic composition containing Ocimum basilicum seed extract | |
| JP4757157B2 (en) | Topical skin preparation | |
| KR102226179B1 (en) | Cosmetic Compositions for Anti-aging Comprising Extracts of Plants | |
| JP2002316937A (en) | Plant extract-containing anti-allergic agent | |
| KR102257448B1 (en) | Cosmetic composition containing black kelp | |
| JP2005035957A (en) | External preparation composition for iontophoresis containing polyglutamic acid or its salt | |
| JP2002363027A (en) | Active oxygen scavenger or cosmetic composition | |
| JP2007045733A (en) | Hyaluronidase inhibitor | |
| KR101934976B1 (en) | Composition for enhancing skin barrier comprising mixture of Diospyros lotus leaf extract and Curcuma longa extract as effective component | |
| JP2004026743A (en) | Polylysine preparation and cosmetic composition containing the same | |
| JP2013107859A (en) | Skin cosmetic preparation for external use comprising connarus extract | |
| KR102199858B1 (en) | Cosmetic Compositions Comprising Complex Extracts of Oriental Medicinal Herbs | |
| KR100789632B1 (en) | Cosmetic for skin whitening containing a herb extract with inhibitory activity of melanin formation | |
| JP2009057312A (en) | Antioxidant and cosmetic containing the same | |
| JP6253702B2 (en) | Cosmetics for external use with Connals louver extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080715 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20101028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110107 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110201 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110404 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110510 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110531 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 4757157 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140610 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |